Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gene Mack
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Beta
- 0.21
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -2.75
Financials
Revenue
$0.00-100.0%Net Income
$-4.68MEBITDA
$-4.54M-2453180.2%Free Cash Flow
$-4.68MEPS (diluted)
$-0.11Shares Outstanding (diluted)
42.88M+780.7%Operating Expenses
$4.68MCash & Debt
$13.08MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-20.16M | $-0.61 |
| 2024 | $0.00 | $-20.41M | $-0.89 |
| 2023 | $55.2K | $-22.27M | $-1.71 |
| 2022 | $140.1K | $-17.59M | $-1.48 |
| 2021 | $165.0K | $-13.89M | $-1.37 |
| 2020 | $28.9K | $-3.58M | $-0.30 |
| 2019 | $41.3K | $-2.19M | $-0.37 |
| 2018 | $20.6K | $-1.11M | $-0.19 |
Valuation
GANXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5d ago·Neutral
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration MDS-UPDRS motor scores demonstrated stability to baseline recorded at study entry with no disease progression among the 12 evaluable participants who completed 12 months of daily oral administration of rexaceract by August 31, 2026
View source ↗ - Newsglobenewswire.com·6d ago·Neutral
…esentation at International Congress of Parkinson's Disease and Movement Disorders BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced a poster presentation at the International Congress of Parkinson's Disease and Movement Disorders, being held October 4-8, 2026, in Seoul, Korea…
View source ↗ - Newsglobenewswire.com·19d ago·Neutral
…erapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference BETHESDA, Md., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain” or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO, will participate in an industry panel and one-on-one meetings at the ROTH Fifth Annual Healthcare Opportunitie…
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.13 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.11 vs $-0.14beat
- Mon, May 11$-0.13 vs $-0.13beat
- Thu, Mar 26$-0.11 vs $-0.14beat
- Wed, Nov 12$-0.15 vs $-0.15beat
- Tue, Aug 12$-0.19 vs $-0.17miss
- Wed, May 14$-0.16 vs $-0.16beat
Estimates and results for GANX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GANX officers and directors.
- Bought
- $24.6m
- Sold
- $5k
11 trades
2 trades
- Mack Genebought
- Islam Khalidbought
- Richman Eric Ibought
- Richman Eric Ibought
- Riley Jeffrey Scottbought
- Alder Matthiassold
- Alder Matthiassold
- Richman Eric Ibought
82 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GANX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.